FOXQ1 and neoplasm: In this clinical trial the effect of phenelzine treatment on a number of mesenchymal markers including CSV, EGFR, FOXQ1, SNAI1 and PD-L1 were assessed using patient derived circulating tumor cells (CTCs) from liquid biopsies taken at baseline and at 29, 57 and 85 days post start of phenelzine therapy.